| abstract |
The present invention relates to dosages and administration regimens of anti-C5 antibodies, particularly anti-C5 antibody covalizumab, for use in methods of treating or preventing C5-related diseases in a subject, including diseases including Paroxysmal nocturnal hemoglobinuria (PNH). Dosages and treatment regimens of the invention comprise administering to the subject a loading dose of an anti-C5 antibody, preferably the anti-C5 antibody covalizumab, followed by one or more maintenance doses of the anti-C5 antibody, wherein all The administered initial loading dose is administered to the subject intravenously, and the remaining loading dose and the maintenance dose are administered subcutaneously at lower doses than the intravenously administered loading dose. |